Tvardi Therapeutics, Inc. (TVRD) Stock Forecast & Price Target
Tvardi Therapeutics, Inc. · NASDAQ
$1.83+0.05 (+2.81%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Tvardi Therapeutics, Inc, 3 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $10.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.00 sits 228% above the current $1.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.49 next quarter toward $-2.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold120%
Sell120%
Strong Sell00%
Based on 5 analysts giving stock ratings to Tvardi Therapeutics, Inc.
As of Aug, 3 of 5 firms rate TVRD a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
TVRD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.49
Range $-0.85 – $-0.13 · 8 analysts · -37% YoY
Next period, 8 analysts expect Tvardi Therapeutics, Inc. to earn $-0.49 a share (range $-0.85 – $-0.13), versus $-0.78 a year earlier. Full-year consensus is $-2.37, growing to $-2.27 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tvardi Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TVRD.
#1
Yasmeen Rahimi
Piper Sandler · Rank #176
Buy
$13.00+610.4% to target
Overall win rate
35%
+ Follow
#2
Jay Olson
Oppenheimer · Rank #354
Buy
$10.00+446.4% to target
Overall win rate
33%
+ Follow
#3
Julian Harrison
BTIG
Buy
$5.00+173.2% to target
Coverage
—
+ Follow
#4
Ryan Deschner
Raymond James
Buy
$10.00+446.4% to target
Coverage
—
+ Follow
#5
Etzer Darout
Barclays
Sell
$3.00+63.9% to target
Coverage
—
+ Follow
TVRD stock forecast FAQ
What is TVRD's average 12-month price target?+
The 5 analysts with a live target average $6.00 for Tvardi Therapeutics, Inc. over the next 12 months, ranging from a $10.00 high to a $3.00 low.
Is TVRD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for TVRD?+
The Street-high target is $10.00 (Raymond James), and the Street-low is $3.00 (Barclays). The average of all 5 active targets is $6.00.
How many Wall Street analysts cover TVRD?+
5 analysts have an active rating on Tvardi Therapeutics, Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TVRD?+
Among analysts who currently cover TVRD, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #176). Their current call is Buy with a $13.00 target.
What is Tvardi Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.49 per share (range $-0.85 – $-0.13) across 8 analysts. Full-year EPS is projected at $-2.37, rising to $-2.27 the following year.
How much revenue is Tvardi Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TVRD lately?+
As of Aug, 3 of 5 firms rate TVRD a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TVRD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
